Long‐term complete remission after interferon treatment in a case of multicentric castelman's disease

Tamayo, Manuel; Gonzalez, Celia; Majado, Maria Juliana; Candel, R; Ramos, José Carlos Castro

doi:10.1002/ajh.2830490422

Cited by 19 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternative approaches with good response reported after the failure of conventional chemotherapy include administration of high dose melphalan with autologous bone marrow transplantation, 53 anti-IL-6 monoclonal antibody, 51 and interferon-alpha. 57 We report a complete remission of multicentric-HV disease following treatment with suramin, 59 a known antiparasitic drug and reverse transcriptase inhibitor with proven antiproliferative effects on lymphoid cells. 60 In summary, CD is a poorly understood disease that creates both diagnostic and therapeutic dilemmas for the treating physician.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The management of unicentric and multicentric Castleman's disease

Bowne

Lewis

Filippa

et al. 1999

Cancer

394

335

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

“…Only anecdotal cases treated with a variety of single agents or combination regimens were found in the literature 19,20,[51][52][53][54][55][56][57][58] (Table 6). The use of high dose corticosteroids alone is associated with incomplete responses in most patients.…”

Section: Discussionmentioning

confidence: 99%

The management of unicentric and multicentric Castleman's disease

Bowne

Lewis

Filippa

et al. 1999

Cancer

394

335

View full text Add to dashboard Cite

“…There have been isolated case reports of successful treatment of both human immunodeficiency virus-related [51,52] and non-HIV-related [53][54][55] multicentric CD with IFN-␣. Standard dosage 3 to 5 times 106/µL subcutaneously 3 times a week.…”

Section: Interferon-␣mentioning

confidence: 97%

Treatment of castleman’s disease

Dispenzieri

Gertz

2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Castleman's disease (CD) was first described in 1954 and further defined in 1956 by Castleman. Since then much has been learned about the heterogeneity of this condition. Subsequently, three pathologic classifications have been developed (hyaline vascular variant, plasma cell variant, and mixed variant) and two clinical classifications (unicentric [unifocal or localized] and multicentric [multifocal or generalized]). The pathology found with the unicentric presentation is most commonly that of the HV variant. It responds well to surgical resection and is associated with a benign course. The multicentric presentation is rarely composed of lymph nodes with HV pathology, but rather with the plasma cell or mixed pathology. This presentation requires systemic therapy and prognosis is guarded. Associated systemic symptoms are common. There is an increased incidence of CD in patients with HIV. The human herpes virus-8 is associated with nearly all of the HIV-associated CD cases and nearly 50% of non-HIV cases. Interleukin (IL)-6 has also been shown to play a significant role in the pathogenesis of the disease. Paraneoplastic and autoimmune entities are not uncommon in the disorder. Variable benefit has been achieved with single agent chemotherapy, combination chemotherapy, interferon (IFN)-alpha, rituximab, anti-IL-6 receptor antibodies, and thalidomide. Patients with CD are at increased risk for developing frank malignant lymphoma.

show abstract

“…One case complicated by pancytopenia required treatment interruption [56], even though interferon was well tolerated in most cases. Interestingly, interferon-␣ was successful in yielding long-term complete remission in patients off treatment for as long as 4 years [57]. The precise underlying mechanisms of these salutary outcomes have not been fully characterized but could be a result of several diverse biologic effects of interferon, including inhibition of trans-signaling via downregulation of IL-6R, antiviral effects such as inhibition of HHV-8 replication, and upregulation of human leukocyte antigen class 1 expression on HHV-8 -infected cells leading to cell-mediated destruction [58,59].…”

Section: Immunomodulatorsmentioning

confidence: 99%

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

2011

View full text Add to dashboard Cite

Castleman's disease is a rare lymphoproliferative disorder in which there has been recent progress in elucidating underlying mechanisms with potential therapeutic implications. Unicentric Castleman's disease is an indolent condition that is often treated with local approaches. In contrast, patients with multicentric Castleman's disease (MCD) have a less favorable prognosis and require systemic treatment. Cytotoxic chemotherapy, with its attendant risk for toxicity, has been widely used to treat MCD, with variable efficacy. The discovery of putative etiologic factors and targets in MCD, particularly human herpes virus 8, CD20, and interleukin (IL)-6, has been translated into the use of rituximab and anti-IL-6-based therapy, as well as antiviral agents. In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology. The Oncologist 2011;16:497-511

show abstract

Long‐term complete remission after interferon treatment in a case of multicentric castelman's disease

Cited by 19 publications

References 7 publications

The management of unicentric and multicentric Castleman's disease

The management of unicentric and multicentric Castleman's disease

Treatment of castleman’s disease

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

Contact Info

Product

Resources

About